Prognostic implications of receptor discordance between primary and recurrent breast cancer

Akiko Matsumoto, Hiromitsu Jinno, Takeshi Murata, Tomoko Seki, Maiko Takahashi, Tetsu Hayashida, Kaori Kameyama, Yuukou Kitagawa

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Discordance rates of hormone receptor (HR) and human epidermal growth factor-2 (HER2) status between primary and recurrent breast cancer were reported to be in the wide range of 10–40 %, although its prognostic relevance remains to be elucidated.

Methods: Fifty-five breast cancer patients had biopsies or resections of recurrent lesions. Pathological assessments of the HR and HER2 status of primary and recurrent lesions were performed in a single laboratory at Keio University Hospital. Tumors were classified as luminal (HR+ and HER2−), luminal/HER2 (HR+ and HER2+), HER2 (HR− and HER2+), or triple negative (HR− and HER2−).

Results: Discordance rates in estrogen receptor (ER), progesterone receptor (PgR) and HER2 status between primary tumors and recurrent lesions were 16.4, 30.9 and 10.2 %, respectively. Overall, 14 patients (25.5 %) changed subtypes at recurrent lesions. Patients with a gain in ER and PgR status had a significantly longer disease-free interval compared with the corresponding concordant-negative patients (ER: 99.0 vs. 18.5 months, p = 0.037, PgR: 141.0 vs. 24.4 months, p = 0.011). Patients with a loss of HER2 status experienced a trend toward shorter time to progression, compared with patients who maintained HER2 positivity (4.0 vs. 18.4 months, p = 0.051).

Conclusions: Discordance in receptor status between primary and recurrent breast cancers were seen in 10–30 %. A gain in HR status was significantly associated with better prognosis.

Original languageEnglish
JournalInternational Journal of Clinical Oncology
DOIs
Publication statusAccepted/In press - 2014 Oct 29

Fingerprint

Epidermal Growth Factor
Hormones
Breast Neoplasms
Progesterone Receptors
Estrogen Receptors
Neoplasms
human ERBB2 protein
Biopsy

Keywords

  • Biopsy
  • Breast cancer
  • Discordance
  • Prognosis
  • Receptor
  • Recurrence

ASJC Scopus subject areas

  • Oncology
  • Surgery
  • Hematology

Cite this

@article{baf09aff335f4cc485eb2e30a1b49596,
title = "Prognostic implications of receptor discordance between primary and recurrent breast cancer",
abstract = "Background: Discordance rates of hormone receptor (HR) and human epidermal growth factor-2 (HER2) status between primary and recurrent breast cancer were reported to be in the wide range of 10–40 {\%}, although its prognostic relevance remains to be elucidated.Methods: Fifty-five breast cancer patients had biopsies or resections of recurrent lesions. Pathological assessments of the HR and HER2 status of primary and recurrent lesions were performed in a single laboratory at Keio University Hospital. Tumors were classified as luminal (HR+ and HER2−), luminal/HER2 (HR+ and HER2+), HER2 (HR− and HER2+), or triple negative (HR− and HER2−).Results: Discordance rates in estrogen receptor (ER), progesterone receptor (PgR) and HER2 status between primary tumors and recurrent lesions were 16.4, 30.9 and 10.2 {\%}, respectively. Overall, 14 patients (25.5 {\%}) changed subtypes at recurrent lesions. Patients with a gain in ER and PgR status had a significantly longer disease-free interval compared with the corresponding concordant-negative patients (ER: 99.0 vs. 18.5 months, p = 0.037, PgR: 141.0 vs. 24.4 months, p = 0.011). Patients with a loss of HER2 status experienced a trend toward shorter time to progression, compared with patients who maintained HER2 positivity (4.0 vs. 18.4 months, p = 0.051).Conclusions: Discordance in receptor status between primary and recurrent breast cancers were seen in 10–30 {\%}. A gain in HR status was significantly associated with better prognosis.",
keywords = "Biopsy, Breast cancer, Discordance, Prognosis, Receptor, Recurrence",
author = "Akiko Matsumoto and Hiromitsu Jinno and Takeshi Murata and Tomoko Seki and Maiko Takahashi and Tetsu Hayashida and Kaori Kameyama and Yuukou Kitagawa",
year = "2014",
month = "10",
day = "29",
doi = "10.1007/s10147-014-0759-2",
language = "English",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Prognostic implications of receptor discordance between primary and recurrent breast cancer

AU - Matsumoto, Akiko

AU - Jinno, Hiromitsu

AU - Murata, Takeshi

AU - Seki, Tomoko

AU - Takahashi, Maiko

AU - Hayashida, Tetsu

AU - Kameyama, Kaori

AU - Kitagawa, Yuukou

PY - 2014/10/29

Y1 - 2014/10/29

N2 - Background: Discordance rates of hormone receptor (HR) and human epidermal growth factor-2 (HER2) status between primary and recurrent breast cancer were reported to be in the wide range of 10–40 %, although its prognostic relevance remains to be elucidated.Methods: Fifty-five breast cancer patients had biopsies or resections of recurrent lesions. Pathological assessments of the HR and HER2 status of primary and recurrent lesions were performed in a single laboratory at Keio University Hospital. Tumors were classified as luminal (HR+ and HER2−), luminal/HER2 (HR+ and HER2+), HER2 (HR− and HER2+), or triple negative (HR− and HER2−).Results: Discordance rates in estrogen receptor (ER), progesterone receptor (PgR) and HER2 status between primary tumors and recurrent lesions were 16.4, 30.9 and 10.2 %, respectively. Overall, 14 patients (25.5 %) changed subtypes at recurrent lesions. Patients with a gain in ER and PgR status had a significantly longer disease-free interval compared with the corresponding concordant-negative patients (ER: 99.0 vs. 18.5 months, p = 0.037, PgR: 141.0 vs. 24.4 months, p = 0.011). Patients with a loss of HER2 status experienced a trend toward shorter time to progression, compared with patients who maintained HER2 positivity (4.0 vs. 18.4 months, p = 0.051).Conclusions: Discordance in receptor status between primary and recurrent breast cancers were seen in 10–30 %. A gain in HR status was significantly associated with better prognosis.

AB - Background: Discordance rates of hormone receptor (HR) and human epidermal growth factor-2 (HER2) status between primary and recurrent breast cancer were reported to be in the wide range of 10–40 %, although its prognostic relevance remains to be elucidated.Methods: Fifty-five breast cancer patients had biopsies or resections of recurrent lesions. Pathological assessments of the HR and HER2 status of primary and recurrent lesions were performed in a single laboratory at Keio University Hospital. Tumors were classified as luminal (HR+ and HER2−), luminal/HER2 (HR+ and HER2+), HER2 (HR− and HER2+), or triple negative (HR− and HER2−).Results: Discordance rates in estrogen receptor (ER), progesterone receptor (PgR) and HER2 status between primary tumors and recurrent lesions were 16.4, 30.9 and 10.2 %, respectively. Overall, 14 patients (25.5 %) changed subtypes at recurrent lesions. Patients with a gain in ER and PgR status had a significantly longer disease-free interval compared with the corresponding concordant-negative patients (ER: 99.0 vs. 18.5 months, p = 0.037, PgR: 141.0 vs. 24.4 months, p = 0.011). Patients with a loss of HER2 status experienced a trend toward shorter time to progression, compared with patients who maintained HER2 positivity (4.0 vs. 18.4 months, p = 0.051).Conclusions: Discordance in receptor status between primary and recurrent breast cancers were seen in 10–30 %. A gain in HR status was significantly associated with better prognosis.

KW - Biopsy

KW - Breast cancer

KW - Discordance

KW - Prognosis

KW - Receptor

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=84908301791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908301791&partnerID=8YFLogxK

U2 - 10.1007/s10147-014-0759-2

DO - 10.1007/s10147-014-0759-2

M3 - Article

C2 - 25348193

AN - SCOPUS:84938743046

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

ER -